-
公开(公告)号：US10760065B2
公开(公告)日：2020-09-01
申请号：US14475785
申请日：2014-09-03
Applicant: Massachusetts Institute of Technology
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , Mark Kyle Mimee
Abstract: Various aspects and embodiments of the invention are directed to methods and compositions for reversing antibiotic resistance or virulence in and/or destroying pathogenic microbial cells such as, for example, pathogenic bacterial cells. The methods include exposing microbial cells to a delivery vehicle with at least one nucleic acid encoding an engineered autonomously distributed circuit that contains a programmable nuclease targeted to one or multiple genes of interest.
-
公开(公告)号：US20180305703A1
公开(公告)日：2018-10-25
申请号：US15924045
申请日：2018-03-16
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , James Collins , Russell-John Krom
CPC classification number: C12N15/74 , C12N7/00 , C12N15/70 , C12N2795/14132 , C12N2795/14143 , C12N2795/14171 , C12N2830/55
Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
-
Patent Agency Ranking
公开(公告)号：US20220033830A1
公开(公告)日：2022-02-03
申请号：US17189113
申请日：2021-03-01
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , James Collins , Russell-John Krom
Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
-
公开(公告)号：US20210071159A1
公开(公告)日：2021-03-11
申请号：US16936881
申请日：2020-07-23
Applicant: Massachusetts Institute of Technology
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , Mark K. Mimee
Abstract: Various aspects and embodiments of the invention are directed to methods and compositions for reversing antibiotic resistance or virulence in and/or destroying pathogenic microbial cells such as, for example, pathogenic bacterial cells. The methods include exposing microbial cells to a delivery vehicle with at least one nucleic acid encoding an engineered autonomously distributed circuit that contains a programmable nuclease targeted to one or multiple genes of interest.
-
公开(公告)号：US20150004705A1
公开(公告)日：2015-01-01
申请号：US14320965
申请日：2014-07-01
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , James Collins , Russell-John Krom
IPC: C12N15/74
CPC classification number: C12N15/74 , C12N7/00 , C12N15/70 , C12N2795/14132 , C12N2795/14143 , C12N2795/14171 , C12N2830/55
Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
Abstract translation: 本公开的各个方面和实施方案涉及在体内功能化内源性细菌的方法和组合物。 所述方法包括向内源细菌细胞递送重组噬菌体或被设计成含有至少一个遗传回路的噬菌粒。
-
公开(公告)号：US09957511B2
公开(公告)日：2018-05-01
申请号：US14320965
申请日：2014-07-01
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , James Collins , Russell-John Krom
CPC classification number: C12N15/74 , C12N7/00 , C12N15/70 , C12N2795/14132 , C12N2795/14143 , C12N2795/14171 , C12N2830/55
Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
-
公开(公告)号：US10968454B2
公开(公告)日：2021-04-06
申请号：US15924045
申请日：2018-03-16
Inventor： Timothy Kuan-Ta Lu , Robert James Citorik , James Collins , Russell-John Krom
Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
